EHA26: BTK combos in CLL/SLL showing earlier line promise
At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma …
Post
-
-
EHA26: J&J’s multiple myeloma therapies impress with new data
Johnson & Johnson (J&J) has shared data from several studies evaluating two of its approved therapies in multiple myeloma (MM) …
-
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate. The …
-
Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its …
-
EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML
At the European Hematology Association (EHA) 2026 Congress, updated results from the Phase Ia RevSTAR-123 trial were presented on June …
-
EHA26: BTK combos in CLL/SLL showing earlier line promise
At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma …
-
EHA26: J&J’s multiple myeloma therapies impress with new data
Johnson & Johnson (J&J) has shared data from several studies evaluating two of its approved therapies in multiple myeloma (MM) …
-
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate. The …
-
Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its …
-
EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML
At the European Hematology Association (EHA) 2026 Congress, updated results from the Phase Ia RevSTAR-123 trial were presented on June …
-
XBiotech to commence V-SPINE trial enrolment for vilamakitug
XBiotech is set to go ahead with patient enrolment for the V-SPINE (PT064) Phase II clinical trial to assess the …
-
Takeda reports pivotal data from FirstLight and RadiantLight trials
Takeda has reported pivotal results from its Phase III FirstLight and RadiantLight studies of oveporexton (TAK-861), an oral orexin receptor …
-
Podcast: AI in oncology – the trials, tribulations and opportunities
In recent years, artificial intelligence (AI) has become one of the largest talking points within the pharma space – a …
-
How gene therapies are changing the Qualified Person role in the EU
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however, …
-
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety data from …
